| 112P Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase … T Yoshino, TW Kim, WP Yong, KK Shiu, BV Jensen, LH Jensen, D Smith, ... Annals of Oncology 31, S1284-S1285, 2020 | 1 | 2020 |
| 2235P Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer PP Vitiello, R Chilà, P Battuello, V Battaglieri, V Amodio, G Grasso, ... Annals of Oncology 34, S1151, 2023 | | 2023 |
| 2777 Lavage of the uterine cavity for early and differential diagnosis of serous ovarian cancer E Maritschnegg, Y Wang, NM Pecha, R Horvat, E Van Nieuwenhuysen, ... European Journal of Cancer 3 (51), S557, 2015 | | 2015 |
| 315 Disappearing Colorectal Metastases After Chemotherapy: Should We Be Concerned? MG van Vledder, MC de Jong, TM Pawlik, RD Schulick, L Diaz, MA Choti Gastroenterology 138 (5), S-849-S-850, 2010 | | 2010 |
| 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016 A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ... Journal for immunotherapy of cancer 4, 1-106, 2016 | 10 | 2016 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
| 396O Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high … T André, M Amonkar, J Norquist, KK Shiu, TW Kim, BV Jensen, LH Jensen, ... Annals of Oncology 31, S409, 2020 | 14 | 2020 |
| 432P Pembrolizumab (pembro) for previously treated, microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis … DT Le, L Diaz, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ... Annals of Oncology 32, S550, 2021 | 5 | 2021 |
| 45. Clonal hematopoiesis in childhood cancer survivors I Chan, D Friedman, C Moskowitz, S Li, K Turner, J Liu, N Bouvier, ... Cancer Genetics 278, 14, 2023 | | 2023 |
| 597 Molecular Markers Help Define Cyst Type in the Pancreas: An International, Multicenter Study of Over 300 Cysts S Springer, M Dal Molin, Y Wang, C Douville, D Masica, A Blackford, ... Gastroenterology 150 (4), S121, 2016 | 1 | 2016 |
| A bacterial protein enhances the release and efficacy of liposomal cancer drugs I Cheong, X Huang, C Bettegowda, LA Diaz Jr, KW Kinzler, S Zhou, ... Science 314 (5803), 1308-1311, 2006 | 201 | 2006 |
| A blueprint to advance colorectal cancer immunotherapies DT Le, VM Hubbard-Lucey, MA Morse, CR Heery, A Dwyer, TH Marsilje, ... Cancer immunology research 5 (11), 942-949, 2017 | 65 | 2017 |
| A combination of molecular markers and clinical features improve the classification of pancreatic cysts S Springer, Y Wang, M Dal Molin, DL Masica, Y Jiao, I Kinde, A Blackford, ... Gastroenterology 149 (6), 1501-1510, 2015 | 446 | 2015 |
| A comprehensive comparison of early-onset and average-onset colorectal cancers A Cercek, WK Chatila, R Yaeger, H Walch, GDS Fernandes, A Krishnan, ... JNCI: Journal of the National Cancer Institute 113 (12), 1683-1692, 2021 | 108 | 2021 |
| A comprehensive noninvasive approach for the stratification of lung cancer patients for targeted therapies. DM Murphy, SV Angiuoli, B Chesnick, K Galens, S Jones, M Kadan, ... Journal of Clinical Oncology 33 (15_suppl), e22086-e22086, 2015 | 2 | 2015 |
| A Decade of Cancer Discovery LA Diaz, LC Cantley Cancer Discovery 11 (4), 795-797, 2021 | 2 | 2021 |
| A first-in-human phase I study of MORAb-004 (M4), a humanized monoclonal antibody recognizing endosialin (TEM-1), in patients with solid tumors. LA Diaz, NS Azad, MM Gounder, CM Coughlin, J Fishel, D O'Shannessy, ... Journal of Clinical Oncology 30 (15_suppl), 3016-3016, 2012 | 1 | 2012 |
| A first-in-human phase I study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors. RD Carvajal, MM Gounder, CM Coughlin, J Fishel, J Heyburn, ... Journal of Clinical Oncology 29 (15_suppl), 3086-3086, 2011 | 3 | 2011 |
| A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors LA Diaz Jr, CM Coughlin, SC Weil, J Fishel, MM Gounder, S Lawrence, ... Clinical cancer research 21 (6), 1281-1288, 2015 | 66 | 2015 |
| A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors LAD Jr, CM Coughlin, SC Weil, J Fishel, MM Gounder, S Lawrence, ... | | |
Bert VogelsteinJohns Hopkins在 jhmi.edu 的电子邮件经过验证
